BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Paratek Pharmaceuticals, Inc. 

75 Kneeland Street

Boston  Massachusetts  02111  U.S.A.
Phone: 617-275-0040 Fax: 617-275-0039


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases. Paratek has a particular focus on developing new therapeutics for the infectious disease market to combat the problem of antibiotic resistance. Paratek was founded in 1996 by Dr. Stuart B. Levy, the world-renowned expert in antibiotic resistance and Professor of Molecular Biology and Microbiology and of Medicine at Tufts University School of Medicine, and by Dr. Walter Gilbert, the successful biotechnology entrepreneur and well-known Nobel Prize-winning Professor at Harvard University. Paratek was created to harness the 30+ years of research and discovery in mechanisms of antibiotic resistance and tetracycline chemistry by Dr. Levy and his scientific team at Tufts University School of Medicine.

Paratek has established two product development programs to identify and develop multiple products for the treatment of infectious diseases:

  • The Tetracycline Resistance Project (Tet Project), based on expertise in medicinal chemistry
  • The Multiple Antibiotic Resistance Project (Mar Project), based on novel discoveries in pathogen genomics

Senior Management:
Thomas J. Bigger, President & Chief Executive Officer
Stuart B. Levy, M.D., Chief Scientific Officer
Beverly A. Armstrong, Vice President & Chief Financial Officer
George C. Hillman, Executive Vice President & Chief Operating Officer
S. Ken Tanaka, Vice President of Research & Development
Dennis Molnar, Executive Director of Corporate Development

Board of Directors
Walter Gilbert, Ph.D., Chairman
Stuart B. Levy, M.D., Vice Chairman & CSO
Thomas J. Bigger, President & CEO, Director
Kalevi Kurkijarvi, Ph.D., Director
Kenneth J. Novack, Director
Sir Mark Richmond, Ph.D., Director
Patricia Smith, M.D., Director
Pieter Strijkert, Ph.D., Director

Last Updated: 04-23-02


 Key Statistics


Email: ir@paratekpharm.com
Ownership: Private

Web Site: Paratek Pharmaceuticals, Inc.
Employees: 76
Symbol: 
 









 Company News
Paratek Pharmaceuticals, Inc. Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline 1/4/2013 8:55:03 AM    More...
Paratek Pharmaceuticals, Inc. Files for a $92 Million IPO 9/28/2012 6:33:43 AM    More...
Paratek Pharmaceuticals, Inc. Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 5/22/2012 7:06:53 AM    More...
Paratek Pharmaceuticals, Inc. Wins Agreement With FDA on Special Protocol Assessment (SPA) for Phase 3 Study in Community-Acquired Bacterial Pneumonia (CABP) 3/28/2012 7:31:15 AM    More...
Paratek Pharmaceuticals, Inc. and Families Of Spinal Muscular Atrophy Announced a Multi-Million Dollar Award from the National Institute of Neurological Diseases and Stroke to Advance a Drug Candidate for Spinal Muscular Atrophy 10/15/2009 8:47:01 AM    More...
Paratek Pharmaceuticals, Inc., Novartis AG (JOBS) Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3 10/8/2009 6:47:20 AM    More...
Paratek Pharmaceuticals, Inc. Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 10/27/2008 8:39:20 AM    More...
Trial Paratek Pharmaceuticals, Inc. Antibiotics Help Against "Superbug", University of Virginia Study 10/27/2008 7:30:08 AM    More...
Paratek Pharmaceuticals, Inc. to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 10/14/2008 11:17:02 AM    More...
Paratek Pharmaceuticals, Inc. Completes $40 Million Private Placement 4/16/2008 7:02:52 AM    More...
1234